CA2535401A1 - Composition emulsionnee contenant de la dapsone - Google Patents

Composition emulsionnee contenant de la dapsone Download PDF

Info

Publication number
CA2535401A1
CA2535401A1 CA002535401A CA2535401A CA2535401A1 CA 2535401 A1 CA2535401 A1 CA 2535401A1 CA 002535401 A CA002535401 A CA 002535401A CA 2535401 A CA2535401 A CA 2535401A CA 2535401 A1 CA2535401 A1 CA 2535401A1
Authority
CA
Canada
Prior art keywords
percent
composition according
emulsive composition
dapsone
emulsive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002535401A
Other languages
English (en)
Other versions
CA2535401C (fr
Inventor
Robert William Lathrop
David W. Osborne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Qlt Usa, Inc.
Robert William Lathrop
David W. Osborne
Atrix Laboratories, Inc.
Allergan Sales, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Usa, Inc., Robert William Lathrop, David W. Osborne, Atrix Laboratories, Inc., Allergan Sales, Llc filed Critical Qlt Usa, Inc.
Publication of CA2535401A1 publication Critical patent/CA2535401A1/fr
Application granted granted Critical
Publication of CA2535401C publication Critical patent/CA2535401C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2535401A 2003-08-13 2004-08-13 Composition emulsionnee contenant de la dapsone Active CA2535401C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49491203P 2003-08-13 2003-08-13
US60/494,912 2003-08-13
PCT/US2004/026447 WO2005016296A1 (fr) 2003-08-13 2004-08-13 Composition emulsionnee contenant de la dapsone

Publications (2)

Publication Number Publication Date
CA2535401A1 true CA2535401A1 (fr) 2005-02-24
CA2535401C CA2535401C (fr) 2011-07-26

Family

ID=34193253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2535401A Active CA2535401C (fr) 2003-08-13 2004-08-13 Composition emulsionnee contenant de la dapsone

Country Status (6)

Country Link
EP (1) EP1675563A4 (fr)
JP (1) JP2007533606A (fr)
AU (1) AU2004264964A1 (fr)
CA (1) CA2535401C (fr)
MX (1) MXPA06001713A (fr)
WO (1) WO2005016296A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108147A1 (fr) * 2008-02-27 2009-09-03 Qlt Usa, Inc. Dapsone pour traiter la rosacée
EP2922528B1 (fr) * 2012-11-20 2017-05-31 Allergan, Inc. Compositions topiques de dapsone et de dapsone/adapalène et leurs méthodes d'utilisation
WO2019236374A2 (fr) * 2018-06-04 2019-12-12 Arcutis, Inc. Méthode et formulation pour améliorer le temps de latence de pénétration de la peau du roflumilast
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721242A (en) * 1993-06-17 1998-02-24 Hoffmann-La Roche Inc. Antibiotic combination
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US20030157036A1 (en) * 2002-02-20 2003-08-21 Osborne David W. Topical dapsone for the treatment of acne
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6056955A (en) * 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections

Also Published As

Publication number Publication date
EP1675563A1 (fr) 2006-07-05
WO2005016296A1 (fr) 2005-02-24
EP1675563A4 (fr) 2009-07-15
CA2535401C (fr) 2011-07-26
AU2004264964A1 (en) 2005-02-24
MXPA06001713A (es) 2007-01-26
JP2007533606A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
FR2890559B1 (fr) Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
AU678039B2 (en) Stable topical retinoid compositions
US4052513A (en) Stable topical anesthetic compositions
US4912124A (en) Antifungal dermatological solution
US4178373A (en) Coal tar gel composition
PL177592B1 (pl) Kompozycja farmaceutyczna lub weterynaryjna w postaci kremu
US4963555A (en) Formulations of heterocyclic compounds
US6281236B1 (en) Oil-in-water emulsion with improved stability
CA1172169A (fr) Composes heterocycliques
CA2469028A1 (fr) Composition pharmaceutique sous forme de gel ou de solution a base de dihydrotestosterone, son procede de preparation et ses utilisations
EP0255964A1 (fr) Agent de bronzage de la peau
US6495602B1 (en) Topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs
CA2535401A1 (fr) Composition emulsionnee contenant de la dapsone
EE03088B1 (et) Viirusvastaselt aktiivne farmatseutiline õlivesiemulsioon, mis sisaldab 9-[(2-hüdroksüetoksü)metüül]guaniini (atsükloviiri) või selle soola või estrit
JP2002527391A (ja) ビタミンａおよびビタミンｅを含む眼科用組成物の使用
KR870001865A (ko) 우레탄을 함유하는 수성분산제
US8546364B2 (en) Stabilized steroid composition and method for its preparation
JPH0812568A (ja) 化粧料
JPH0418010A (ja) Ｗ／ｏ／ｗ型乳化化粧料
EP0860480A1 (fr) Formulations de décapants pour peinture, leur préparation et leur utilisation
US8389502B2 (en) Stabilized steroid composition and method for its preparation
US6288121B1 (en) Nimesulide topical formulations in the form of liquid crystals
WO2024054489A2 (fr) Formulations ignifuges et procédés d'utilisation
JP2022096990A (ja) 外用乳化組成物
JPS6185313A (ja) 外用製剤

Legal Events

Date Code Title Description
EEER Examination request